Compare Stocks: EPRX, LKFT, IMCR, and SEPN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$6.68	$6.60	$5.12 ▼ $9.32	$434.33M	1.08	306,937 shs	174,227 shs
IMCR Immunocore	$36.62	$33.81	$27.56 ▼ $40.71	$1.89B	0.74	410,103 shs	300,326 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$28.88	$28.76	$25.68 ▼ $37.78	$1.90B	0.27	275,858 shs	143,741 shs
SEPN Septerna	$38.91	$37.29	$11.70 ▼ $51.10	$1.82B	2.29	464,534 shs	385,855 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	0.00%	-0.74%	+4.37%	-2.62%	+24.63%
IMCR Immunocore	0.00%	-0.70%	+8.31%	+25.71%	+13.66%
LKFT Lakefront Biotherapeutics American Depositary Shares	0.00%	+0.28%	+6.14%	+4.87%	-8.14%
SEPN Septerna	0.00%	-2.73%	+12.95%	+29.79%	+221.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$6.68	$6.60	$5.12 ▼ $9.32	$434.33M	1.08	306,937 shs	174,227 shs
IMCR Immunocore	$36.62	$33.81	$27.56 ▼ $40.71	$1.89B	0.74	410,103 shs	300,326 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$28.88	$28.76	$25.68 ▼ $37.78	$1.90B	0.27	275,858 shs	143,741 shs
SEPN Septerna	$38.91	$37.29	$11.70 ▼ $51.10	$1.82B	2.29	464,534 shs	385,855 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	0.00%	-0.74%	+4.37%	-2.62%	+24.63%
IMCR Immunocore	0.00%	-0.70%	+8.31%	+25.71%	+13.66%
LKFT Lakefront Biotherapeutics American Depositary Shares	0.00%	+0.28%	+6.14%	+4.87%	-8.14%
SEPN Septerna	0.00%	-2.73%	+12.95%	+29.79%	+221.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPRX Eupraxia Pharmaceuticals	2.89	Moderate Buy	$18.00	169.46% Upside
IMCR Immunocore	2.69	Moderate Buy	$56.38	53.95% Upside
LKFT Lakefront Biotherapeutics American Depositary Shares	2.33	Hold	$30.67	6.19% Upside
SEPN Septerna	2.82	Moderate Buy	$52.44	34.78% Upside

Current Analyst Ratings Breakdown

Latest EPRX, LKFT, IMCR, and SEPN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/24/2026	IMCR Immunocore	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	IMCR Immunocore	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$50.00
8/21/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/19/2026	SEPN Septerna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$38.00 ➝ $48.00
8/13/2026	SEPN Septerna	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$43.00 ➝ $62.00
8/12/2026	SEPN Septerna	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $50.00
8/12/2026	SEPN Septerna	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $60.00
8/11/2026	SEPN Septerna	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$49.00
8/11/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$30.00 ➝ $26.00
8/11/2026	SEPN Septerna	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A
IMCR Immunocore	$400.02M	4.71	N/A	N/A	$7.52 per share	4.87
LKFT Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.51	$0.73 per share	39.78	$47.57 per share	0.61
SEPN Septerna	$45.95M	39.53	N/A	N/A	$8.53 per share	4.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPRX Eupraxia Pharmaceuticals	-$38.58M	-$1.02	N/A	N/A	N/A	N/A	-63.97%	-43.32%	11/3/2026 (Estimated)
IMCR Immunocore	-$35.51M	-$0.37	N/A	146.48	N/A	-4.20%	-4.54%	-1.66%	11/5/2026 (Estimated)
LKFT Lakefront Biotherapeutics American Depositary Shares	$363.05M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SEPN Septerna	-$48.88M	-$0.54	N/A	N/A	N/A	-24.51%	-9.57%	-6.28%	11/9/2026 (Estimated)

Latest EPRX, LKFT, IMCR, and SEPN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	EPRX Eupraxia Pharmaceuticals	-$0.25	-$0.23	+$0.02	-$0.23	N/A	N/A
8/10/2026	Q2 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$0.9672	$0.04	+$1.0072	$0.04	$7.29 million	$15.47 million
8/10/2026	Q2 2026	SEPN Septerna	-$0.4260	-$0.29	+$0.1360	-$0.29	$19.22 million	$26.75 million
8/7/2026	Q2 2026	IMCR Immunocore	-$0.01	-$0.02	-$0.01	-$0.02	$148.57 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A	N/A	N/A
SEPN Septerna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPRX Eupraxia Pharmaceuticals	0.02	16.00	16.00
IMCR Immunocore	0.94	4.47	4.44
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	32.84	32.72
SEPN Septerna	N/A	4.99	4.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EPRX Eupraxia Pharmaceuticals	N/A
IMCR Immunocore	84.50%
LKFT Lakefront Biotherapeutics American Depositary Shares	32.46%
SEPN Septerna	N/A

Insider Ownership

Company	Insider Ownership
EPRX Eupraxia Pharmaceuticals	N/A
IMCR Immunocore	10.10%
LKFT Lakefront Biotherapeutics American Depositary Shares	2.91%
SEPN Septerna	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EPRX Eupraxia Pharmaceuticals	29	65.02 million	N/A	N/A
IMCR Immunocore	320	51.50 million	46.30 million	Optionable
LKFT Lakefront Biotherapeutics American Depositary Shares	1,310	65.90 million	63.98 million	Optionable
SEPN Septerna	N/A	46.68 million	43.97 million	N/A

EPRX, LKFT, IMCR, and SEPN Headlines

Recent News About These Companies

BlackRock Inc. Purchases Shares of 1,932,088 Septerna, Inc. $SEPN

1 hour ago | marketbeat.com

Jupiter Topco LLC Invests $43.72 Million in Septerna, Inc. $SEPN

August 28 at 5:35 AM | marketbeat.com

Primecap Management Co. CA Takes $39.10 Million Position in Septerna, Inc. $SEPN

August 27, 2026 | marketbeat.com

Elmind Capital LP Purchases New Holdings in Septerna, Inc. $SEPN

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Buys New Stake in Septerna, Inc. $SEPN

August 26, 2026 | marketbeat.com

Algert Global LLC Grows Stake in Septerna, Inc. $SEPN

August 26, 2026 | marketbeat.com

Septerna names Rajiv Patni as CMO

August 25, 2026 | msn.com

Septerna Appoints Rajiv Patni as Chief Medical Officer

August 25, 2026 | tipranks.com

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

August 25, 2026 | globenewswire.com

Septerna, Inc. (NASDAQ:SEPN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 22, 2026 | marketbeat.com

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Septerna (NASDAQ:SEPN) Stock

August 21, 2026 | americanbankingnews.com

Septerna (NASDAQ:SEPN) Stock Price Down 8% - Time to Sell?

August 20, 2026 | marketbeat.com

Septerna (NASDAQ:SEPN) Price Target Raised to $48.00

August 19, 2026 | marketbeat.com

4,211,659 Shares in Septerna, Inc. $SEPN Acquired by Trv Gp Vi LLC

August 19, 2026 | marketbeat.com

Trv Gp V LLC Takes Position in Septerna, Inc. $SEPN

August 19, 2026 | marketbeat.com

37,700 Shares in Septerna, Inc. $SEPN Purchased by Renaissance Technologies LLC

August 15, 2026 | marketbeat.com

Major Insider Move Shakes Up Septerna, Inc. Shares

August 14, 2026 | tipranks.com

HC Wainwright Predicts Septerna's Q3 Earnings (NASDAQ:SEPN)

August 14, 2026 | marketbeat.com

Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 25,000 Shares

August 14, 2026 | insidertrades.com

Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 25,000 Shares of Stock

August 13, 2026 | marketbeat.com

Septerna (NASDAQ:SEPN) Trading Down 6.1% - Here's Why

August 13, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, LKFT, IMCR, and SEPN Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

$6.68 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$6.68 0.00 (-0.07%)

As of 03:59 AM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Immunocore NASDAQ:IMCR

$36.62 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$36.69 +0.07 (+0.19%)

As of 05:18 AM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$28.88 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Septerna NASDAQ:SEPN

$38.91 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$38.90 -0.01 (-0.04%)

As of 04:35 AM Eastern

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, LKFT, IMCR, and SEPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, LKFT, IMCR, and SEPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, LKFT, IMCR, and SEPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, LKFT, IMCR, and SEPN Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

Immunocore NASDAQ:IMCR

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Septerna NASDAQ:SEPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, LKFT, IMCR, and SEPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, LKFT, IMCR, and SEPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, LKFT, IMCR, and SEPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, LKFT, IMCR, and SEPN Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

Immunocore NASDAQ:IMCR

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Septerna NASDAQ:SEPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools